Amneal taps Todd Branning as CFO
Amneal has named a generics industry veteran as its new CFO.
Todd Branning, the company's new vice president and CFO, will be responsible for leading Amneal's global finance strategies, including oversight for finance and accounting, internal audit, investor relations and corporate communications, and information technology, Amneal said.
Branning succeeds Bryan Reasons, who will remain with the company through the end of February 2019.
Branning has more than 25 years of experience leading the finance and accounting strategies, as well as corporate financial planning and analysis, at public companies, primarily in the pharmaceuticals sector. Most recently, he served as senior vice president and CFO of Teva Pharmaceuticals' multibillion dollar global generic medicines division.
"With Amneal's key integration milestones largely complete, we are now building, leveraging and optimizing our infrastructure," said Amneal president and CEO Rob Stewart." Todd's deep experience driving finance, accounting and change management strategies across complex and rapidly evolving organizations will be particularly valuable as we continue executing our strategy to deliver growth and sustainable value. We look forward to his leadership and contributions."
"On behalf of our entire company, I want to thank Bryan for his contributions," Stewart said. "Bryan played an important role in preparing Impax for our successful combination with Amneal. He was instrumental in helping us capture cost synergies at an accelerated pace, and spearheaded the efforts to build the financial compliance foundation upon which Amneal can now move forward as a publicly-traded company. I look forward to continuing to work with him through this transition and wish him well in his future endeavors."
Branning has a master's degree in business administration from Carnegie Mellon University and a bachelor's degree in commerce and business administration from the University of Miami. He is a certified public accountant and has completed a CFO certification program from the Wharton School at the University of Pennsylvania.
"I am honored to join the Amneal team at this exciting point in the evolution of our business," Branning said. "We have a solid generic and specialty business foundation, a diversified pipeline and strong cash flow to support organic and inorganic growth opportunities. I look forward to working with Rob and the rest of the management team to help Amneal achieve its full potential."
Todd Branning, the company's new vice president and CFO, will be responsible for leading Amneal's global finance strategies, including oversight for finance and accounting, internal audit, investor relations and corporate communications, and information technology, Amneal said.
Branning succeeds Bryan Reasons, who will remain with the company through the end of February 2019.
Branning has more than 25 years of experience leading the finance and accounting strategies, as well as corporate financial planning and analysis, at public companies, primarily in the pharmaceuticals sector. Most recently, he served as senior vice president and CFO of Teva Pharmaceuticals' multibillion dollar global generic medicines division.
"With Amneal's key integration milestones largely complete, we are now building, leveraging and optimizing our infrastructure," said Amneal president and CEO Rob Stewart." Todd's deep experience driving finance, accounting and change management strategies across complex and rapidly evolving organizations will be particularly valuable as we continue executing our strategy to deliver growth and sustainable value. We look forward to his leadership and contributions."
"On behalf of our entire company, I want to thank Bryan for his contributions," Stewart said. "Bryan played an important role in preparing Impax for our successful combination with Amneal. He was instrumental in helping us capture cost synergies at an accelerated pace, and spearheaded the efforts to build the financial compliance foundation upon which Amneal can now move forward as a publicly-traded company. I look forward to continuing to work with him through this transition and wish him well in his future endeavors."
Branning has a master's degree in business administration from Carnegie Mellon University and a bachelor's degree in commerce and business administration from the University of Miami. He is a certified public accountant and has completed a CFO certification program from the Wharton School at the University of Pennsylvania.
"I am honored to join the Amneal team at this exciting point in the evolution of our business," Branning said. "We have a solid generic and specialty business foundation, a diversified pipeline and strong cash flow to support organic and inorganic growth opportunities. I look forward to working with Rob and the rest of the management team to help Amneal achieve its full potential."